In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Clinical trials for a laser treatment targeting this common eye disease will begin in Finland next spring, and researchers hope it could become available to patients within three years. About one in ...

EyePoint Pharmaceuticals (EYPT) just shared that its pivotal Phase 3 trial for DURAVYU in wet age-related macular degeneration has passed the second independent safety committee review. This marks a ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

Aalto University scientists have created a laser-based treatment that uses gentle heat to stop the progression of dry macular ...

Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...

Support local journalism. A digital subscription is incredibly affordable and makes you the most informed person around. Click here and subscribe today Many frightening thoughts may go through your ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 3% after the FDA approved its EYLEA HD injection for treating macular edema following retinal vein occlusion (RVO) with up to every ...